Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Open in API
Filings indexed 1,765 across all filing types
Latest filing 2023-05-30 Regulatory Filings
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the stock exchanges (BSE and NSE) regarding the audio recording of a conference call with analysts and investors about the audited financial results for the quarter and year ended 31st March 2023. It references a previous letter and provides a link to the audio recording on the company's website. The document does not contain the transcript itself, nor does it include financial data or detailed analysis. It is essentially an announcement about the availability of the conference call recording. Given the short length (1488 characters) and the nature of the content (announcement of a conference call recording), this fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a full Call Transcript (CT) or Earnings Release (ER).
2023-05-30 English
Related Party Transactions
Regulatory Filings Classification · 95% confidence The document is a detailed disclosure of Related Party Transactions for the half year ended March 31, 2023, submitted pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It contains extensive tabular data on transactions between the listed entity and its related parties, including subsidiaries and key management personnel, covering sales, purchases, remuneration, commissions, and loans. The document is not a full financial report like an Annual Report or Interim Report but a regulatory compliance disclosure specific to related party transactions. It is not an announcement of a report but the actual disclosure itself, with substantive data. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-05-30 English
Pursuant to Regulation 42 of Listing Regulations, the Company has fixed Friday, 23rd June, 2023 as the Record Date for taking record of the Members of the Company entitled for the purpose ....
Notice of Dividend Amount Classification · 95% confidence The document is a short notice from Torrent Pharmaceuticals Limited addressed to the stock exchange regarding the fixation of a Record Date for determining shareholders entitled to receive the final dividend for the fiscal year 2022-23. It references Regulation 42 of the SEBI Listing Regulations and specifies the date for the record. The document does not contain any financial statements, detailed financial data, or report content. It is an announcement related to dividend payment logistics rather than the dividend amount itself or a full dividend report. Given the content and length (1705 characters), this fits the category of a Notice of Dividend Amount or related announcement. However, since it only fixes the Record Date and does not specify dividend amount or payment details, it is best classified as a Notice of Dividend Amount (DIV) as per the definitions, which includes announcements about dividend payment dates and related shareholder entitlements.
2023-05-30 English
Record Date
Notice of Dividend Amount Classification · 95% confidence The document is a short notice dated 30th May 2023 from Torrent Pharmaceuticals Limited addressed to the National Stock Exchange of India. It informs about the Record Date fixed for determining shareholders entitled to receive the final dividend for the fiscal year 2022-23, if declared. The content is a formal announcement related to dividend payment details and does not contain any financial statements, detailed reports, or management commentary. The document length is only 1705 characters, indicating it is a brief announcement rather than a full report. According to the classification rules, such announcements about dividend record dates fall under the category of Notice of Dividend Amount (DIV).
2023-05-30 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is a presentation to analysts on the audited financial results for the quarter and year ended 31st March 2023. It includes revenue summaries and financial data for Q4 FY 2022-23. The document is titled as a presentation and contains detailed financial figures and analysis, which aligns with the definition of an Investor Presentation (IP). The document length is 1926 characters, which is short but contains substantive financial data and is not merely an announcement or a certification. Therefore, it is classified as an Investor Presentation.
2023-05-30 English
Presentation to analysts on Audited Financial Results for the quarter and year ended 31st March, 2023
Investor Presentation Classification · 95% confidence The document is a letter addressed to the stock exchanges (BSE and NSE) dated 30th May 2023, enclosing a presentation made to analysts on the audited financial results for the quarter and year ended 31st March 2023. The text includes summary revenue data for Q4 FY 2022-23. The document is relatively short (1926 characters) and explicitly states it is a presentation to analysts on audited financial results. This matches the definition of an Investor Presentation (IP), which is a detailed presentation for investors focusing on financials, strategy, and market position. It is not the full annual report or earnings release, but a presentation accompanying the results. Therefore, the correct classification is Investor Presentation (IP).
2023-05-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.